Patients with specific FTO variants, for example, may show stronger appetite suppression with higher-dose semaglutide, while those with certain GIPR polymorphisms might benefit from tirzepatide's dual GLP-1/GIP mechanism
And that's what we're forecasting as well, I believe
Although most of the above drugs have been studied in clinical trials, most clinical trials are phase I/II trials
Some evidence-based guidelines support first-line use
showed GLP-1 RA prevents the expected decline in cerebral glucose metabolism and increases a surrogated measure of the number of glucose transporters at the blood-brain barrier, although no benefit in cognition was observed [11, 12]
(59-62) Ill be sure to let you know when I learn more about the status of NAC on the market